Oppenheimer Asset Management Inc. Lowers Stake in NeoGenomics, Inc. $NEO

Oppenheimer Asset Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 41.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,276 shares of the medical research company’s stock after selling 12,923 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in NeoGenomics were worth $134,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NEO. Brooklyn Investment Group purchased a new position in shares of NeoGenomics during the 1st quarter valued at $35,000. CWM LLC lifted its position in shares of NeoGenomics by 42.6% in the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 1,883 shares in the last quarter. AlphaQuest LLC purchased a new position in shares of NeoGenomics in the first quarter valued at about $60,000. Moors & Cabot Inc. purchased a new position in shares of NeoGenomics in the first quarter valued at about $95,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of NeoGenomics in the first quarter valued at about $178,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Trading Up 0.1%

Shares of NEO stock opened at $9.78 on Tuesday. The stock’s 50 day simple moving average is $8.83 and its two-hundred day simple moving average is $7.77. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $19.11. The company has a market cap of $1.27 billion, a PE ratio of -11.11 and a beta of 1.61. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.58.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The business had revenue of $187.80 million for the quarter, compared to the consensus estimate of $183.85 million. During the same quarter in the prior year, the firm posted $0.05 earnings per share. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on NEO. BTIG Research reissued a “neutral” rating on shares of NeoGenomics in a report on Wednesday, July 30th. Morgan Stanley set a $8.00 target price on shares of NeoGenomics and gave the stock an “equal weight” rating in a report on Wednesday, July 30th. Leerink Partners set a $14.00 target price on shares of NeoGenomics in a report on Tuesday, October 28th. Stephens boosted their price target on shares of NeoGenomics from $6.50 to $11.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 2nd. Finally, William Blair reiterated a “market perform” rating on shares of NeoGenomics in a research note on Tuesday, July 29th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $13.11.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.